There are currently 56 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156
Recruiting
This is a multinational, multicenter, double-blind, placebo-controlled, parallel-group Phase 2, 4-arm study in adult participants with moderate to severe AD who are inadequately controlled with topical therapies or for whom such topical therapies are inadvisable and who are candidates for systemic therapy. Participants will be randomized to receive SAR444656 dose 1, dose 2, dose 3 or matching placebo. Participants who meet inclusion/exclusion criteria will be stratified for randomization by se... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: Clear Dermatology & Aesthetics Center Site Number: 8400003, Scottsdale, Arizona +27 locations
Conditions: Atopic Dermatitis
Register for Updates
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
NCT05721937
Recruiting
The purpose of this observational study is to learn about the safety of abrocitinib (CIBINQO) in pregnant women and the offspring. The study is seeking participants who: * Are currently or recently pregnant * Receive at least one dose of CIBINQO at any time during pregnancy or prior to pregnancy OR have a diagnosis of moderate-to-severe atopic dermatitis All participants in this study will receive treatment according to routine care, as this is an observational study. The exposed group will c... Read More
Gender:
FEMALE
Ages:
0 years and above
Trial Updated:
02/28/2025
Locations: Pfizer, New York, New York
Conditions: Atopic Dermatitis
Register for Updates
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
NCT06564389
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis. An additional goal is to assess the pharmacodynamics of PF-07832837 in participants with moderate to severe AD, including potential effects on clinical signs and symptoms
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
02/28/2025
Locations: Anaheim Clinical Trials, LLC, Anaheim, California
Conditions: Healthy Participants, Atopic Dermatitis
Register for Updates
Bodewell Products for the Treatment of Atopic Dermatitis
NCT05566262
Recruiting
This study aims to examine the safety and efficacy of topical application of the Bodewell eczema products
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
02/25/2025
Locations: The University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Atopic Dermatitis
Register for Updates
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359
Recruiting
The main purpose of this study is to measure the effect, safety and how well the body absorbs lebrikizumab in pediatric participants 6 months to \<18 years of age with moderate-to-severe atopic dermatitis (AD).
Gender:
ALL
Ages:
Between 6 months and 17 years
Trial Updated:
02/24/2025
Locations: Clinical Research Center of Alabama, Birmingham, Alabama +98 locations
Conditions: Atopic Dermatitis, Eczema
Register for Updates
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407
Recruiting
The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life. The trial will last for up to 40 weeks. There will be up to 15 visits, 3 of which will be conducted by phone. The first part of the trial is called a screening period and will last up to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/21/2025
Locations: LEO Pharma Investigational Site, Birmingham, Alabama +75 locations
Conditions: Atopic Dermatitis, Atopic Hand Eczema
Register for Updates
Topical ENS-002 for Atopic Dermatitis in Adults
NCT06469385
Recruiting
The goal of this study is to determine the safety and effects of ENS-002, a live biotherapeutic product (LBP) consisting of commensal, clonal, non-pathogenic bacteria in participants with atopic dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/19/2025
Locations: Encore Medical Research, Hollywood, Florida +2 locations
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema
Register for Updates
Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism
NCT04455906
Recruiting
This protocol is primarily looking to see if the IL-4Ra R576 polymorphism is associated with increased clinical, immunological and microbial markers of disease activity in patients with Atopic dermatitis.
Gender:
ALL
Ages:
Between 6 years and 65 years
Trial Updated:
02/15/2025
Locations: Boston Children's Hospital, Boston, Massachusetts
Conditions: Atopic Dermatitis
Register for Updates
A Study of Barzolvolimab in Patients With Atopic Dermatitis
NCT06727552
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/13/2025
Locations: Cahaba Dermatology & Skin Health Center, Birmingham, Alabama +5 locations
Conditions: Atopic Dermatitis
Register for Updates
The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.
NCT05696392
Recruiting
The purpose of the study is to evaluate the effect of ruxolitinib cream on sleep disturbances with participants with Atopic Dermatitis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/07/2025
Locations: First Oc Dermatology, Fountain Valley, California +29 locations
Conditions: Atopic Dermatitis
Register for Updates
Seal, Stopping Eczema and Allergy Study
NCT03742414
Recruiting
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Gender:
ALL
Ages:
Between 1 week and 12 weeks
Trial Updated:
02/06/2025
Locations: Sean N. Parker Center for Allergy & Asthma Research at Stanford University, Palo Alto, California +4 locations
Conditions: Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Register for Updates
Longitudinal Endotyping Of Atopic Dermatitis Through Transcriptomic Skin Analysis
NCT05436535
Recruiting
This is a multi-center, longitudinal study which will characterize the gene expression profiles and transcriptomic endotypes that underlie mild and moderate-severe Atopic dermatitis (AD) and will determine changes in these expression patterns and endotypes in response to standard-of-care treatment. Participants will complete up to ten scheduled study visits with assessment of topical steroid response and dupilumab response (if uncontrolled with topical steroids). Skin samples will be collected a... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
02/04/2025
Locations: University of California, San Diego: Dermatology Clinical Trials Unit, La Jolla, California +9 locations
Conditions: Atopic Dermatitis
Register for Updates